Financial report for the period 1 January 2022 to 31 March
|PROFIT AND LOSS||Q1 2022||Q1 2021||Growth|
|Diluted earnings per share (in DKK)||6.22||5.45||14%||N/A|
* CER: Constant exchange rates (average 2021).
Lars Fruergaard Jørgensen, president and CEO: "We are very pleased with the sales growth in the first three months of 2022 which is driven by increasing demand for our GLP-1-based treatments. The sales momentum has enabled us to raise our outlook for the full year. Within R&D, we are encouraged by the first phase 3 trial with once-weekly insulin icodec showing the potential to reduce the number of injections and improve quality of life for people needing insulin treatment as well as the progress with our late-stage pipeline in Rare disease."
On 29 April 2022 at 13.00 CEST, corresponding to 07.00 am EDT, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 49,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
|5 June 2022||Investor event at ADA in New Orleans|
|4 August 2022||Financial statement for the first six months of 2022|
|2 November 2022||Financial statement for the first nine months of 2022|
|1 February 2023||Financial statement for 2022|
|Contacts for further information|
|Ambre Brown Morley||+45 3079 firstname.lastname@example.org|
|Natalia Salomao Abrahao (US)||+1 848 304 email@example.com|
|Daniel Muusmann Bohsen||+45 3075 firstname.lastname@example.org|
|Ann Søndermølle Rendbæk||+45 3075 email@example.com|
|David Heiberg Landsted||+45 3077 firstname.lastname@example.org|
|Jacob Martin Wiborg Rode||+45 3075 email@example.com|
|Mark Joseph Root (US)||+1 848 213 firstname.lastname@example.org|
Further information about Novo Nordisk is available on novonordisk.com.
Company announcement No 33 / 2022